Raymond James analyst Jayson Bedford downgraded Integra LifeSciences to Market Perform from Outperform while removing his $54 price target on the shares. The analyst sees the company as a better second half of 2018 story with fewer catalysts in the first half of the year. A lack of product drivers could weigh on investors' confidence that Integra can return to a sustainable 5%-plus organic revenue growth profile, Bedford told investors earlier in a research note. He does not see the company's organic growth exceeding 5% until the second half of 2018.